Skip to main content
. 2020 Jan 30;5(2):e131437. doi: 10.1172/jci.insight.131437

Figure 1. VH chain gene mutation frequency of Env-specific mAbs isolated from the RV144, RV305, or RV305a HIV-1 clinical trials.

Figure 1

B cells were antigen specific single-cell sorted or isolated from memory B cell culture. The antibody VH and VL chain genes were RT-PCR amplified, Sanger sequenced, and analyzed with Cloanalyst (45). Env reactivity and epitope specificity was determined by transiently expressing mAbs and assaying by ELISA. MAbs were isolated from 8 RV144 vaccinees, 14 RV305 vaccinees, and 5 RV305a vaccinees, of which 5 were studied in all 3 clinical trials. All PBMCs used for mAb isolation were collected 2 weeks after the final boost in each clinical trial. Dashed line indicates 2% VH chain gene mutation frequency. Numbers of mAbs analyzed are in parentheses.